• About us
• Contact

Advertisement

Organisation › Details

UCL Technology Fund (UCL TF)

The UCL Technology Fund is dedicated to investing in intellectual property commercialisation opportunities arising from UCL’s world-class research base, focusing in particular on the physical and life sciences. The Fund supports UCL in achieving the full potential of innovations that have prospects for outstanding societal and market impact, right through the development journey from initial proof of concept to practical commercial application. The Fund is managed by Albion Capital, one of the largest independent venture capital investors in the UK, in collaboration with UCL Business. *

 

	Start	2016-10-05 existent
	Group	University College London (UCL)
	Industry	venture capital
	Industry 2	IP services
	Region	London, Greater London
	Country	United Kingdom (GB)
	City	n. a.
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Freeline Therapeutics Ltd.. (6/19/18). "Press Release: Freeline Secures Over £88 Million of Funding". London.
		Record changed: 2023-10-10

Advertisement

More documents for University College London (UCL)

• [1] AstronauTx Ltd.. (10/9/23). "Press Release: AstronauTx Closes £48 Million ($61 Million) Series A Financing to Create New Treatments for Alzheimer’s Disease". London....
• [2] Tenpoint Therapeutics Ltd.. (7/12/23). "Press Release: Tenpoint Therapeutics Launches with $70 Million Series A Financing to Reverse Vision Loss Through Engineered Cell-based Therapeutics and In Vivo Reprogramming". London....
• [3] Synthego Corporation. (5/11/23). "Press Release: Synthego Opens State-of-the-Art GMP Guide RNA Manufacturing Facility to Enable CRISPR Genomic Medicines". Redwood City, CA....
• [4] UCL Business. (8/3/20). "Press Release: UCL Technology Fund Announces First Close of £100m Fund 2"....
• [5] Apollo Therapeutics. (7/21/20). "Press Release: UCLB and Apollo Therapeutics Secure First Out-licensing Deal to Deerfield, a Leading U.S. Healthcare Investment Firm". London & New York, NY....
• [6] UCL Technology Fund. (9/16/19). "Press Release: Echopoint Raises £2.8m to Address the ‘Grey Zone’ of Heart Disease treatment"....
• [7] Bruker Corporation. (9/2/19). "Press Release: Bruker Launches Highest Resolution Large-Format Bio-AFM System". Münster....
• [8] University College London (UCL). (8/13/19). "Press Release: Biotech Startup Secures £6.5m for Dementia Research"....
• [9] MeiraGTx Holdings plc. (5/14/19). "Press Release: MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency". London & New York, NY....
• [10] ArcherDX, Inc.. (3/28/19). "Press Release: ArcherDX Announces Collaboration with University College London to Investigate the Novel Use of Cell-Free Tumor DNA to Detect Disease Recurrence in Lung Cancer Patients". Boulder, CO....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.